DESIGN OF NOVEL ASTHMA THERAPEUTICS

Information

  • Research Project
  • 2417525
  • ApplicationId
    2417525
  • Core Project Number
    R43AI040744
  • Full Project Number
    1R43AI040744-01A1
  • Serial Number
    40744
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/1997 - 27 years ago
  • Project End Date
    3/14/1998 - 26 years ago
  • Program Officer Name
  • Budget Start Date
    9/15/1997 - 27 years ago
  • Budget End Date
    3/14/1998 - 26 years ago
  • Fiscal Year
    1997
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/19/1997 - 27 years ago
Organizations

DESIGN OF NOVEL ASTHMA THERAPEUTICS

Asthma is an allergic inflammatory disorder characterized predominantly by an eosinophilic infiltrate into the airways. Eosinophils are thought to be the major effector cells mediating tissue injury and hyperresponsiveness. Therefore, it is likely that blocking the mechanisms responsible for the selective emigration of eosinophils could result in attenuation of the disease. Eotaxin, a potent and selective chemokine for eosinophils, signals through the chemokine receptor CKR3 which is exclusively expressed on eosinophils. Because of their eosinophilic specificity, eotaxin and CKR3 may play a pivotal role in the preferential migration of eosinophils into the airways. Consequently, CKR3 would appear to be an attractive target for drug development. The goal of Phase I research is to identify potent eotaxin analog antagonists. In addition, we expect to obtain information on the molecular basis for eotaxin binding and signalling through CKR3 which will be valuable for drug design. We will study the nature of the molecular recognition between eotaxin and its receptor using a mutational and functional approach. Specifically, we will: 1) Express, purify and characterize a) site directed point mutations of eotaxin, b) N-terminal extensions of eotaxin, and c) hybrid chemokines; 2) Characterize the binding and functional properties of the eotaxin mutants in in vitro assays using human eosinophils and CKR3 cell transfectants; 3) Evaluate the binding and functional properties of antagonists using eosinophils from species appropriate for in vivo asthma studies. PROPOSED COMMERCIAL APPLICATION: The long-term goal of this project is the development of antagonists for CKR3 potential therapeutics for asthma. Phase I studies could identify an antagonist that might have commercial potential. In long-term goal of this project is the development of antagonists for CKR3 potential therapeutics for asthma. Phase I studies could identify an antagonist that might have commercial potential. In addition, these studies could also provide valuable information for rational drug design.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG3
  • Study Section Name
  • Organization Name
    LEUKOSITE, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02142
  • Organization District
    UNITED STATES